Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: 21-hydroxylase Deficiency Clear all

Conditions: Polycystic Ovary Syndrome, Obesity, Hyperandrogenism
Interventions: Dexamethasone, rhCG; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years to 18 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Adrenal Hyperplasia, Congenital
Interventions: Hydrocortisone sodium acetate; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Years to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Congenital Adrenal Hyperplasia
Interventions: Pre-Screening; Other
Lead sponsor: Adrenas Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort, Cortef, Placebo; Drug · Other
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more

Conditions: Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Luminex Corporation; Industry
Eligibility: 1 Day to 7 Days
Enrollment: 7,462 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Albany, New York • Nashville, Tennessee • Taylorsville, Utah

Conditions: CAH - Congenital Adrenal Hyperplasia
Interventions: NBI-74788; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Aurora, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Abiraterone acetate, Placebo, Hydrocortisone, Fludrocortisone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 9 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more

Conditions: Congenital Adrenal Hyperplasia, Healthy
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 9 Years to 40 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Polycystic Ovary Syndrome
Interventions: Salsalate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Tildacerfont/Placebo; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Congenital Adrenal Hyperplasia, 21-OHD
Interventions: Tildacerfont; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 2 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 13
States / cities: Sacramento, California • San Diego, California • Chicago, Illinois + 10 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: NBI-77860; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 12 Years to 18 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Seattle, Washington

Conditions: Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Interventions: Metyrapone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Polycystic Ovary Syndrome, Hyperandrogenism, Puberty
Interventions: Phenotype/genotype assessment; Other
Lead sponsor: University of Virginia; Other
Eligibility: 8 Years to 17 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Congenital Adrenal Hyperplasia
Interventions: Tildacerfont/Placebo; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more

Conditions: Polycystic Ovary Syndrome
Interventions: Yasmin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 40 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adrenal Hyperplasia, Polycystic Ovarian Syndrome, Oligomenorrhea, Obesity, Hyperandrogenism
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 16 Years to 29 Years · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adrenal Hyperplasia, Congenital
Interventions: Not listed
Lead sponsor: Office of Rare Diseases (ORD); NIH
Eligibility: 12 Years and older
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions: atumelnant (CRN04894); Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Pasadena, California • Ann Arbor, Michigan • Minneapolis, Minnesota + 5 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Hydrocortisone; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Adrenal Hyperplasia, Hyperplasia, Adrenal Hyperplasia, Congenital Disorders, Adrenocortical Hyperfunction, Disorders of Sex Development, Urogenital Abnormalities, Genetic Diseases, Inborn, Steroid Metabolic Diseases, Inborn, Adrenal Gland Disease, Hydrocortisone
Interventions: Subcutaneous hydrocortisone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 4 Years to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Disorder of Sex Development, Intersex Conditions, Congenital Adrenal Hyperplasia, Hypospadias
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more

Conditions: Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Interventions: Metyrapone 250 mg Oral Tablets, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Ovarian Contribution to Androgen Production in Adolescent Girls

Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia

A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

Clinical Evaluation of NeoPlex4 Assay and NeoPlex System

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

Androgen Reduction in Congenital Adrenal Hyperplasia

Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH

Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

Continuous Versus Cyclical OCP Use in PCOS

Adrenal Hyperplasia Among Young People With PCOS

Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

Decision Support for Parents Receiving Information About Child's Rare Disease

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS